Skip to main content

Table 5 Sensitivity analysis: number of cases avoided for the different boys and girls vaccination strategies versus boys and girls base case analysis (vaccine coverage rate: 70%, lifelong protection) and the corresponding relative reductions

From: Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

Absolute reduction (increase) of remaining cases (n) versus base case GNV vaccination strategy Relative reduction (increase) of remaining cases (%) versus base case GNV vaccination strategy
Duration of protection Lifetime 32 years      
Coverage rate 50% 90% 70% 50% 90%      
Vaccination strategy B C D E F B C D E F
Female Genital warts 40,271 −24,568 68,313 108,009 38,674 160.6 −98.0 272.5 430.8 154.3
  Cervical cancer 3,212 −1,692 5,685 8,853 3,092 148.4 −78.2 262.7 409.1 142.9
  Vulvar cancer 337 −158 568 925 285 130.3 −61.2 219.5 357.4 110.1
  Vaginal cancer 139 −63 236 388 116 140.3 −63.7 238.2 392.2 117.6
  Anal cancer 357 −192 598 978 300 104.6 −56.3 175.1 286.4 88.0
  Head/neck cancer 305 −163 504 832 250 104.6 −55.9 173.0 285.3 85.6
  Total cancers 4,351 −2,269 7,591 11,976 4,044 137.9 −71.9 240.6 379.6 128.2
Male Genital warts 49,534 −34,444 77,279 122,846 43,104 140.6 −97.8 219.3 348.6 122.3
  Penile cancers 155 −124 237 358 130 44.1 −35.2 67.3 101.6 37.0
  Anal cancers 225 −129 351 576 173 98.0 −56.0 152.7 250.6 75.1
  Head/neck cancer 1,669 −931 2,636 4,331 1,306 108.6 −60.6 171.5 281.8 85.0
  Total cancers 2,050 −1,184 3,224 5,264 1,609 96.7 −55.9 152.2 248.5 75.9
Female + Male Genital warts 89,805 −59,013 145,592 230,855 81,778 148.9 −97.9 241.4 382.8 135.6
Total cancers 6,400 −3,453 10,815 17,240 5,653 121.4 −65.5 205.1 326.9 107.2
  1. HPV, human papillomavirus.
  2. Negative values mean a reduction of the number of HPV burden of the disease and positive values mean an increase of the burden compared with base case boys and girls vaccination strategy (GNV).